Onesource Specialty Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on May 05, 2025.
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Onesource Specialty Pharma (formerly Stelis Biopharma) announced audited financial results for Q4 and full year ended March 31, 2025. Standalone revenue jumped sharply to Rs. 12,995.89 million in FY25 from Rs. 1,719.19 million in FY24, with Q4 FY25 revenue at Rs. 4,774.14 million versus Rs. 3,367.49 million in the previous quarter. The company swung to a standalone profit of Rs. 200 million (continuing operations) for FY25 from a loss of Rs. 3,649.34 million a year ago, while Q4 standalone profit was Rs. 1,748.77 million. Total assets expanded to Rs. 73,904.62 million (from Rs. 13,085.76 million) and reserves surged to Rs. 59,086.58 million, reflecting the merger/restructuring impact including Rs. 19,761.42 million of goodwill. The board also appointed M/s. D V & Associates as Secretarial Auditor for 5 years, approved consolidation of Singapore subsidiaries (Stelis Pte Ltd and Strides Softgel Pte Ltd) into Onesource Specialty Pte Ltd, and confirmed full redemption of 20,000 Non-Convertible Debentures on November 28, 2024. Deloitte Haskins & Sells issued an unmodified opinion on the financials.
Strong turnaround from a heavy FY24 loss to profitability, alongside massive balance sheet expansion tied to the Stelis-Onesource merger, is likely to be viewed positively by investors. The debt redemption and clean auditor opinion reduce near-term risk concerns, while the Singapore consolidation simplifies the group structure.